| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514646 | LILLY | Insulin analogs modified at position 29 of the B chain |
May, 2013
(10 years ago) | |
| US5474978 | LILLY | Insulin analog formulations |
Jun, 2014
(9 years ago) | |
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(3 months from now) | |
Humalog Kwikpen is owned by Lilly.
Humalog Kwikpen contains Insulin Lispro Recombinant.
Humalog Kwikpen has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Humalog Kwikpen are:
- US5514646
- US5474978
Humalog Kwikpen was authorised for market use on 15 November, 2019.
Humalog Kwikpen is available in injectable;injection dosage forms.
Humalog Kwikpen can be used as treatment of diabetes mellitus, use for the treatment of hyperglycemia.
The generics of Humalog Kwikpen are possible to be released after 09 August, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Oct 12, 2015 |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 15 November, 2019
Treatment: Use for the treatment of hyperglycemia; Treatment of diabetes mellitus
Dosage: INJECTABLE;INJECTION
HUMALOG KWIKPEN family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6551992 | ELI LILLY AND CO | Stable insulin formulations |
Jun, 2018
(5 years ago) | |
| US6034054 | ELI LILLY AND CO | Stable insulin formulations |
Jun, 2018
(5 years ago) | |
| US7291132 | ELI LILLY AND CO | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(3 months from now) | |
Humalog Kwikpen is owned by Eli Lilly And Co.
Humalog Kwikpen contains Insulin Lispro Recombinant.
Humalog Kwikpen has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Humalog Kwikpen are:
- US6551992
- US6034054
Humalog Kwikpen was authorised for market use on 26 May, 2015.
Humalog Kwikpen is available in solution;subcutaneous dosage forms.
Humalog Kwikpen can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof..
The generics of Humalog Kwikpen are possible to be released after 09 August, 2024.
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 26 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.
Dosage: SOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN family patents